Spyre Therapeutics (SYRE) Accumulated Depreciation (2015 - 2022)

Spyre Therapeutics has reported Accumulated Depreciation for 8 years, with the latest figure at $4.1 million in Q4 2022.

• For the quarter ending Q4 2022, Accumulated Depreciation rose 47.89% year-over-year to $4.1 million; the trailing twelve-month figure through Dec 2022 stood at $4.1 million (up 47.89% YoY), and the FY2022 full-year result was $4.1 million, up 47.89% from the prior year.
• Accumulated Depreciation for Q4 2022 stood at $4.1 million, up from $2.8 million in the prior quarter.
• The five-year high for Accumulated Depreciation was $4.1 million in Q4 2022, with the low at $752000.0 in Q4 2018.
• Historically, Accumulated Depreciation has averaged $2.1 million across 5 years, with a median of $2.0 million in 2020.
• Annual changes were most pronounced in 2019 — Accumulated Depreciation jumped 40.29% — and 2020, when it jumped 87.96%.
• Spyre Therapeutics' Accumulated Depreciation stood at $752000.0 in 2018, then surged by 40.29% to $1.1 million in 2019, then jumped by 87.96% to $2.0 million in 2020, then jumped by 41.3% to $2.8 million in 2021, then soared by 47.89% to $4.1 million in 2022.
• The last three Accumulated Depreciation figures came in at $4.1 million (Q4 2022), $2.8 million (Q4 2021), and $2.0 million (Q4 2020), per Business Quant data.